Nantbio, Inc.

Immunitybio, Inc.

Nanocav, LLC

Peter Sieling

Kayvan R Niazi

Philip T Liu

Raymond Wong

Patrick Soon-Shiong

Shahrooz Rabizadeh

Annie Shin

Jeffrey Safrit

Elizabeth Gabitzsch

Adrian Rice

Lise Geissert

Leonard Sender

Ting-Hsiang Sherry Wu

Yu-Chun Kung

Ting Wu

Wade Richardson

Krsto Sbutega

Adam D Lazar

Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

Cellular adjuvants for viral infection

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of anti-viral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

SARS-CoV-2 vaccines comprising human adenovirus vectors encoding spike and nucleocapsid-ETSD immunogens

Provided herein are methods of in-vitro primary T cell growth that enrich T cells in a blood sample, stimulate the T cells with anti-CD2, anti-CD3, and/or anti-CD28 and that expand the T cells with a cytokine. Also provided are methods of treating a tumor in a patient using the expanded T cells.

Primary T-cell expansion

Disclosed herein are methods for inducing immunity against a virus such as a coronavirus in the mucosal tissue of a patient, include administering a vaccine composition to the patient by oral administration (e.g., nasal injection, nasal inhalation, oral inhalation, and/or oral ingestion). Also disclosed are compositions for assaying the presence of antiviral antibodies induced by the administered vaccine or the presence of viral proteins in a saliva sample include a stabilizing solution and may also include the use of aragonite particle beads. Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity is bivalent, comprising a nucleic acid encoding a coronavirus 2 nucleocapsid protein CoV2 nucleocapsid protein fused to an endosomal targeting sequence, and a nucleic acid encoding a CoV2 spike protein sequence optimized for cell surface expression.

Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus

Methods and devices are provided for focusing and/or sorting activated T cells. The device comprises a microfluidic channel comprising a plurality of electrodes arranged to provide dielectrophoretic (DEP) forces that are perpendicular to forces from hydrodynamic flows along the channel. The device may be configured to apply voltages to a plurality of electrodes in a first upper region of the microfluidic channel to focus the cells into a single flow, and to apply different voltages to a plurality of electrodes in a second downstream region of the microfluidic channel to sort cells based on size. The output of the microfluidic channel may diverge into multiple channels, wherein cells of various sorted sizes are directed into the appropriate output channel.

Methods of sorting activated T cells using three dimensional dielectrophoresis

Growing community of inventors

Culver City, CA, United States of America

Peter Sieling